Skip to main content

Table 2 Immune checkpoint inhibitors approved for clinical use up to 2021, according to www.fda.gov

From: Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Target Drug name Indication Brand name (company)
CTLA-4 Ipilimumab Melanoma; metastatic melanoma Yervoy (Bristol-Myers Squibb Co.)
CTLA-4 + PD-1 Ipilimumab + nivolumab HCC; metastatic CRC; metastatic melanoma; metastatic RCC; metastatic NSCLC; malignant pleural mesothelioma Yervoy + Opdivo (Bristol-Myers Squibb Co.)
PD-1 Nivolumab HCC; Hodgkin lymphoma; metastatic CRC; metastatic melanoma; melanoma; metastatic RCC; metastatic urothelial carcinoma; metastatic HNSCC; metastatic SCLC; metastatic NSCLC; ESCC Opdivo (Bristol-Myers Squibb Co.)
PD-1 Pembrolizumab HCC; Merkel cell carcinoma; NSCLC; metastatic squamous NSCLC; RCC; melanoma; metastatic gastric cancer; metastatic gastroesophageal junction adenocarcinoma; metastatic urothelial carcinoma; metastatic cervical cancer; Hodgkin lymphoma; metastatic NSCLC; metastatic endometrial cancer; CRC; NMIBC; pancreatic cancer; primary mediastinal B-cell lymphoma; metastatic HNSCC; metastatic tumor mutational burden-high solid tumors; metastatic cSCC, metastatic TNBC Keytruda (Merck & Co. Inc.)
PD-1 Cemiplimab Metastatic cSCC Libtayo (Regeneron Pharmaceuticals Inc. / Sanofi-Aventis SA)
PD-L1 Atezolizumab Metastatic TNBC; metastatic NSCLC; SCLC; metastatic urothelial cancer; HCC; metastatic melanoma Tecentriq (Genentech Inc. / Roche Registration Ltd.)
PD-L1 Durvalumab SCLC; metastatic urothelial cancer; NSCLC Imfinzi (AstraZeneca Pharmaceuticals LP)
PD-L1 Avelumab Metastatic RCC; metastatic urothelial cancer; Merkel cell carcinoma Bavencio (Merck KGaA / Pfizer Inc.)
  1. HCC hepatocellular carcinoma, CRC colorectal cancer, RCC renal cell carcinoma, NSCLC non-small-cell lung cancer, HNSCC head and neck squamous cell carcinoma, SCLC small-cell lung cancer, ESCC esophageal squamous cell carcinoma, NMIBC non-muscle invasive bladder cancer, cSCC cutaneous squamous cell carcinoma, TNBC triple-negative breast cancer